Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03458728 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
A Phase 1 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT03458728 is a Phase 1 study that was terminated before completion, run by Bayer. The registered enrollment target is 31 participants.
The verdict
NCT03458728, a Phase 1 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.
Interventions
- DRUG Copanlisib (BAY806946)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2018-04-30 |
| Est. Completion | 2023-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03458728
The ClinicalTrials.gov registry entry for NCT03458728 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Copanlisib (BAY806946) is the first listed.
NCT03458728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03458728 about?
NCT03458728 is a clinical study titled "Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients". This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.
What is the current status of trial NCT03458728?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2018-04-30. Estimated completion is 2023-02-01.
What interventions are being tested in trial NCT03458728?
The interventions under investigation include: Copanlisib (BAY806946) (DRUG).
Who is sponsoring clinical trial NCT03458728?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.